ClinicalTrials.gg
TerminatedNCT00526071Updated Oct 3, 2018Results posted

Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study

A Phase 2 interventional study of migalastat HCl in Fabry Disease, sponsored by Amicus Therapeutics. Terminated at 8 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-03.

Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 2, Interventional, and Treatment

Why this study was terminated
The Sponsor (Amicus Therapeutics) terminated this study for logistical reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.

Enrollment
8th of 20
23 · median 20
Started
2007
the only one that year
Phase 2
6 of 20
none open now
Registered
5th of 20
by date
Lead sponsor
17 of 20
Amicus Therapeutics

Among the 20 studies testing migalastat in Fabry Disease, this one is the 8th largest by enrollment, is the only one that started in 2007, is one of 6 in phase 2, and was the 5th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About migalastat

migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing migalastat in Fabry Disease, or all of them as a file.
02

Study summary

Study to evaluate the long-term safety, tolerability, and pharmacodynamics (PD) of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease

Read the detailed description

This was a long-term open-label study of migalastat in participants with Fabry disease who were previously enrolled in a Phase 2 study of migalastat (FAB-CL-201 [NCT00214500], FAB-CL-202 [NCT00283959], FAB-CL-203 [NCT00283933], or FAB-CL-204 [NCT00304512]). Participants could enter this extension study immediately upon completion of participation in their previous study of migalastat, or at a later time point. Thus, some participants did not necessarily have continuous treatment with migalastat from the end of the original study to the time of enrollment into this extension study. Participants who enrolled before Protocol Amendment 2 received migalastat 150 milligrams (mg) orally once every other day (QOD). After the amendment, these participants entered a dose escalation period (DEP) at their next scheduled visit. During the DEP, participants received migalastat 250 mg (once daily [QD] for 3 days and 4 days off per week) for the first 2 months. If there were no safety concerns, the dose was then increased to 500 mg QD for 3 days and 4 days off per week). Participants received 500 mg (QD for 3 days and 4 days off per week) for up to 10 months, depending on the approval date of the protocol amendments at each site. An interim review of safety and PD data was performed after all enrolled participants had completed at least 4 months of treatment in the DEP. After the review, the dose and regimen of migalastat was returned to 150 mg QOD for all participants, except those who were on another dose as previously agreed by the investigator and medical monitor.

The sponsor (Amicus Therapeutics) discontinued Study FAB-CL-205 for logistical reasons and not due to either safety concerns or lack of efficacy. Participants who were ongoing in Study FAB-CL-205 at the time of discontinuation were offered participation in another open-label, long-term treatment study of migalastat (AT1001-041 [NCT01458119]). Participants who did not enroll in Study AT1001-041 were contacted by telephone or another suitable method approximately 1 month after the End of Study (EOS) visit to inquire about adverse events and concomitant medications.

03

Conditions studied

  • Fabry Disease

Browse trials for

Keywords

  • Amicus Therapeutics
  • AT1001
  • Galafold
  • Migalastat
  • Substrate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have completed another Phase 2 study of migalastat in Fabry Disease
  • Women of must have had a negative result on their pregnancy test
  • Male and female participants agreed to use a reliable method of during study treatment and for 4 weeks after study treatment termination
  • Were willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Had not completed a Phase 2 study of migalastat in Fabry Disease
  • Had a major protocol violation in the preceding migalastat trial and was discontinued
  • Had undergone or was scheduled to undergo kidney transplantation or was currently on dialysis
  • Had been treated with another drug (except migalastat) within 30 days of study start
  • Had been treated with Fabrazyme® (agalsidase beta), Replagal™ (agalsidase alfa), Glyset® (miglitol), or Zavesca® (miglustat) within 2 weeks prior to enrollment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Migalastat

    Migalastat was administered orally, 150 mg QOD, 250 mg QD for 3 days, 4 days off per week for 2 months, or 500 mg QD for 3 days, 4 days off per week for up to 10 months, depending on the approval date of the protocol amendments at each site. Participants received migalastat for up to 56 months.

    Drug: migalastat HCl

Interventions

06

What researchers measure

Primary outcomes

  1. Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs)

    A TEAE was defined as any adverse event (AE) with start date on or after administration of study drug or pre-existing conditions that worsened on or after the start of the first study drug administration (on Day 1). A severe AE was defined as an AE that was incapacitating and required medical intervention. The number of participants who experienced one or more severe TEAEs after dosing on Day 1 through End of Study (EOS) or follow-up (for participants who did not enroll in Study AT1001-041) are presented. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.

    Time frame: Day 1 (after dosing) through EOS (up to 56 months) or follow-up (28 days after EOS)

Secondary outcomes

  1. Absolute Change From Baseline In α-Galactosidase A (α-Gal A) Activity In Leukocytes To Month 42

    The activity of the α-Gal A enzyme was measured in leukocyte lysate by a validated fluorometric assay method, using 4-methylumbelliferone as a reference. The activity values obtained were normalized to protein (measured using a colorimetric assay). Baseline was defined as the last non-missing pre-treatment value for each participant in his or her respective preceding migalastat Phase 2 study. A negative change from Baseline indicates that α-Gal A activity decreased. α-Gal A activity levels are presented for Baseline and Month 42.

    Time frame: Baseline, Month 42

  2. Pharmacokinetics Of Migalastat As Assessed By Plasma Concentration

    The concentration of migalastat was evaluated in plasma following a dose of 250 mg and 500 mg. Blood samples were taken at trough (predose or Time 0; just prior to the third dose during a 3 day on, 4 days off dosing regimen) and at peak (3 hr postdose; after the third dose during a 3 day on, 4 days off dosing regimen) during the Day 1 (250 mg) and Month 2 (500 mg) visits. This outcome presents the lowest and highest concentrations of migalastat measured in any of the participants for predose and 3 hr postdose.

    Time frame: 0 (predose on Day 1; start of DEP), 3 hr (postdose at Month 2; during DEP])

07

Results

Posted Oct 3, 2018

Participant flow

An open label, long-term extension study for participants who completed one of 4 preceding Phase 2 studies (FAB-CL-201 \[NCT00214500\], FAB-CL-202 \[NCT00283959\], FAB-CL-203 \[NCT00283933\], or FAB-CL-204 \[NCT00304512\]). Participants could enter this study directly upon completion of the previous study or at a later point.

Participant flow — Overall Study
MilestoneMigalastat
Started23
Safety population23
Pharmacodynamic (pd) population23
Amenable population; men11
Amenable population; women5
Non-amenable population; men3
Non-amenable population; women4
Completed17
Not completed6
Withdrew: Adverse event1
Withdrew: Withdrawal by subject1
Withdrew: Lack of response to study drug4

Outcome measures

PrimaryNumber Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs)

A TEAE was defined as any adverse event (AE) with start date on or after administration of study drug or pre-existing conditions that worsened on or after the start of the first study drug administration (on Day 1). A severe AE was defined as an AE that was incapacitating and required medical intervention. The number of participants who experienced one or more severe TEAEs after dosing on Day 1 through End of Study (EOS) or follow-up (for participants who did not enroll in Study AT1001-041) are presented. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.

Time frame:
Day 1 (after dosing) through EOS (up to 56 months) or follow-up (28 days after EOS)
Reported as:
Count of participants · Participants
Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs)
ParticipantsMigalastat
Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs)9
SecondaryAbsolute Change From Baseline In α-Galactosidase A (α-Gal A) Activity In Leukocytes To Month 42

The activity of the α-Gal A enzyme was measured in leukocyte lysate by a validated fluorometric assay method, using 4-methylumbelliferone as a reference. The activity values obtained were normalized to protein (measured using a colorimetric assay). Baseline was defined as the last non-missing pre-treatment value for each participant in his or her respective preceding migalastat Phase 2 study. A negative change from Baseline indicates that α-Gal A activity decreased. α-Gal A activity levels are presented for Baseline and Month 42.

Time frame:
Baseline, Month 42
Reported as:
Mean · nanomoles (nm)/hour (hr)/mg protein
Absolute Change From Baseline In α-Galactosidase A (α-Gal A) Activity In Leukocytes To Month 42
nanomoles (nm)/hour (hr)/mg proteinAmenable Population; MenAmenable Population; WomenNon-amenable Population; MenNon-amenable Population; Women
Baseline2.08 ± 2.43316.84 ± 7.9550.09 ± 0.04714.62 ± 8.944
Month 427.88 ± 8.69118.31 ± 14.186—9.77 ± 5.071
SecondaryPharmacokinetics Of Migalastat As Assessed By Plasma Concentration

The concentration of migalastat was evaluated in plasma following a dose of 250 mg and 500 mg. Blood samples were taken at trough (predose or Time 0; just prior to the third dose during a 3 day on, 4 days off dosing regimen) and at peak (3 hr postdose; after the third dose during a 3 day on, 4 days off dosing regimen) during the Day 1 (250 mg) and Month 2 (500 mg) visits. This outcome presents the lowest and highest concentrations of migalastat measured in any of the participants for predose and 3 hr postdose.

Time frame:
0 (predose on Day 1; start of DEP), 3 hr (postdose at Month 2; during DEP])
Reported as:
Number · nanograms/milliliter
Pharmacokinetics Of Migalastat As Assessed By Plasma Concentration
nanograms/milliliterMigalastat
Predose Lowest Concentration5.94
Predose Highest Concentration313
250 mg 3 hr Postdose Lowest Concentration908
250 mg 3 hr Postdose Highest Concentration5250
500 mg 3 hr Postdose Lowest Concentration113
500 mg 3 hr Postdose Highest Concentration8500

Adverse events

Collected over Day 1 after dosing through EOS (up to 56 months) or follow-up (28 days after EOS). Follow-up was not required for participants who enrolled in Study AT1001-041.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Migalastat—7/23 (30.4%)23/23 (100%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventMigalastat
Atrial FibrillationCardiac disorders2/23
Atrial FlutterCardiac disorders1/23
Atrioventricular BlockCardiac disorders1/23
Cardiac Failure CongestiveCardiac disorders1/23
Ventricular FibrillationCardiac disorders1/23
HyperthyroidismEndocrine disorders1/23
DyspepsiaGastrointestinal disorders1/23
Sensation of Foreign BodyGeneral disorders1/23
Ankle FractureInjury, poisoning and procedural complications1/23
Post Procedural HaemorrhageInjury, poisoning and procedural complications1/23
Most frequent other events
Showing 10 of 68
Most frequent other events
EventMigalastat
ArthralgiaMusculoskeletal and connective tissue disorders9/23
Back painMusculoskeletal and connective tissue disorders8/23
FatigueGeneral disorders8/23
InfluenzaInfections and infestations6/23
Pain in extremityMusculoskeletal and connective tissue disorders6/23
HeadacheNervous system disorders6/23
NasopharyngitisInfections and infestations5/23
SinusitisInfections and infestations5/23
Abdominal pain upperGastrointestinal disorders5/23
DiarrhoeaGastrointestinal disorders5/23

Baseline characteristics

All participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Migalastat
Mean43.1 ± 11.33
Sex: Female, Male
Sex: Female, Male(Participants)Migalastat
Female9
Male14
08

Study locations

8 sites
  • Decatur, Georgia 30033, United States
  • New York, New York 10016, United States
  • Dallas, Texas 78226, United States
  • Parkville, Australia
  • Porto Alegre, Brazil
  • Garches, France
  • London, United Kingdom
  • Salford, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2007 to primary completion in Sep 2012, 59 months.

Results were first posted in Oct 2018, 6 years after primary completion. A results delay was requested in Jul 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2007
First posted
Sep 6, 2007
StartActual
Sep 17, 2007
Primary completionActual
Sep 8, 2012
CompletionActual
Sep 8, 2012
Results delay requested
Jul 18, 2013
Results first posted
Oct 3, 2018
Last update
Oct 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00526071
Responsible party
Sponsor
First posted
Sep 6, 2007
Start date
Sep 17, 2007
Primary completion
Sep 8, 2012
Completion
Sep 8, 2012
Results posted
Oct 3, 2018
Last update
Oct 3, 2018

Study contacts

Medical Monitor, Clinical Research
study director · Amicus Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Migalastat

Start the discussion